Quantifying psilocybin exposure in a natural product-based retreat setting: An observational field method for dose measurement - Pérez Rosal Sergio R.; Faber Sonya C. (Psychedelics, 2026)

Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery model - Albertyn Christopher P.; Richard Jérémie; Shore Ron; Carlson Linda E. (Psychedelics, 2026)

Pupil-DLC: An open-source deep learning pipeline for scalable, marker-less tracking of pupil dynamics across conscious and unconscious states. - Seyfourian P; Marks LC; Claar LD; Nahas Y; Keating M; Koch C; Rembado I (Journal of neuroscience methods, 2026)

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression - Kelly Carlton M.; Fradet Mathieu; Bostian Catherine M.; Donnelly Anna; Ellis Sara; Ostacher Michael; Aaronson Scott; Suppes Trisha (Journal of Affective Disorders, 2026)

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats - Ladislavová Lucie; Kútná Viera; Mazochová Kristýna; Šíchová Klára; Danda Hynek; Lhotková Eva; Uttl Libor; Brejtr Vojtěch; Syrová Kateřina; Mazoch Vladimír; Horsley Rachel; Páleníček Tomáš (Pharmacology Biochemistry and Behavior, 2026)

Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults - Yang Kevin H.; Satybaldiyeva Nora; Kepner Wayne; Friedman Joseph; Ping Siyuan; Leas Eric C. (American Journal of Preventive Medicine, 2026)

Single-crystal structure determination of psilocybin after dehydration - Emmett Sonya K.; Cameron Lee; Hestermann Mark; Holland Darren; Kessler Simon; McFarlane Luke; Chooi Yit-Heng; Moggach Stephen A. (Acta Crystallographica Section C Structural Chemistry, 2026)

Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research. - Husein A; Traylor M; Vest MF; Wood BJ; Brogan M; Thomas A; McNeil S; Bhuiyan MAN; Hendricks P; Kelly JR; Gribben A; Al-Qahtani MM; et al. (Psychedelic medicine (New Rochelle, N.Y.), 2026)

A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. - Rich R; Laird K; Siddarth P; Youssef B; Schwartz GM; Ramos A; Sergi K; Linton M; Schwartzberg L; Kelly DF; Heinzerling KG (Psychedelic medicine (New Rochelle, N.Y.), 2026)

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study. - Back AL; McGregor BA; Billingsley L; Blom D; Callan G; Myers S; Guy J; Kumar S; Layer M; Levin J; Perez J; Thompson P; et al. (Psychedelic medicine (New Rochelle, N.Y.), 2026)

Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress - Ibi Daisuke; Takaba Rika; Yoshida Keisuke; Kawase Ririna; Kitagawa Hiroko; Matsushita Momoko; Ito Kana; Uno Shoya; Nishimura Fumiya; Kitagaki Shinji; Hiramatsu Masayuki (Neuropsychopharmacology Reports, 2026)

Balancing safety and access in Oregon’s psilocybin services - Cheung Katherine; Propes Caleigh; Yaden David B. (International Journal of Drug Policy, 2026)

Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases - Abrahms Zachary N.; Majdi Mohammad; Madsen Siena M.; Morton Chloe J.; Sen Abhishek K.; Fried Niya B.; Sawyer Lily E.; Cegielski Evelyn R.; Spezzano Sean J.; Jones J. Andrew (Metabolic Engineering, 2026)

Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review. - Cruz L; Beserra FR; Freind JMK; Rodrigues SE; Mograbi DC (Journal of clinical psychology, 2026)

Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidence. - Kelly C; Cooley BJ; Zeng L; Hurzeler T; Manning V; McNally GP; Watt J; Haber PS; Morley KC. (Neuroscience and biobehavioral reviews, 2026)

The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults - Region Skane (ClinicalTrials.gov, 2026)

Safety for Home Administration of Microdose Psilocybin Use - Johns Hopkins University (ClinicalTrials.gov, 2026)

Psilocybin Administration With 5-HT1a Blockade - Johns Hopkins University (ClinicalTrials.gov, 2026)

A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans - VA Office of Research; Development (ClinicalTrials.gov, 2026)

Ayahuasca and Salvia divinorum as contrasting modes of consciousness reorganization: Implications for psychedelic-assisted psychotherapy - Brian Ross (Journal of Psychedelic Studies, 2026)

Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis. - Meshkat S; Leung M; Meshkat S; Lin Q; Wijendran D; Reichelt AC; Zhang Y; Burback L; Winkler O; Greenshaw A; Monson CM; Vermetten E; et al. (CNS drugs, 2026)

Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study) - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

Processing Intergenerational Trauma With Psilocybin-Assisted Therapy - Rachel Yehuda (ClinicalTrials.gov, 2026)

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder - Sharmin Ghaznavi (ClinicalTrials.gov, 2026)

PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD) - Nathan Brashares Sackett (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial - Brigham; Women's Hospital (ClinicalTrials.gov, 2026)

Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic framework - Anthony L. Back; Robert Bosnak (Frontiers in Psychiatry, 2026)

Investigating the Effects of Psilocybin on Cognitive Flexibility in Touchscreen and Naturalistic Variations of the Probabilistic Reversal Learning Task - Anderson D; Maillot N; Thomas CW; Golden CT; Gilmour G; Robinson ES. (bioRxiv, 2026)

Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and Colorado - Thompson SM; Effinger DP; Novick AM; Bates SC; Conley AS; Tobin-Campbell C; Epperson CN; Skievaski NR. (medRxiv, 2026)

Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe Anxiety - Salgaço Mateus Kawata; Farias David de Paulo; Souza Mariela Zucolo de; Sartoratto Adilson; Bottino Flavia; Barud Hernane da Silva; Oliveira Fellipe Lopes de; Medeiros Alexandra Ivo de; Raimundo Breno Vilas Boas; Nascimento Victor Hugo; Galdino Taynah P.; Silva Suédina M. L.; et al. (Drugs and Drug Candidates, 2026)

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026) - Anghel Teodora; Cojocaru Adriana; Hogea Lavinia; Costea Iuliana; Marinca Amalia; Dumache Raluca; Nussbaum Laura; Trăilă Iuliana-Anamaria (Journal of Clinical Medicine, 2026)

TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy - M.D. Anderson Cancer Center (ClinicalTrials.gov, 2026)

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors - M.D. Anderson Cancer Center (ClinicalTrials.gov, 2026)

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder - NYU Langone Health (ClinicalTrials.gov, 2026)

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality - The University of Texas Health Science Center; Houston (ClinicalTrials.gov, 2026)

Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids - Roswell Park Cancer Institute (ClinicalTrials.gov, 2026)

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy - M.D. Anderson Cancer Center (ClinicalTrials.gov, 2026)

A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder - Claudio N Soares (ClinicalTrials.gov, 2026)

Psychedelic Therapy for Depression - Saanvi Gutta (2026)

Psilocybin-associated microRNA changes in the pig brain: Establishing an nCounter pipeline for cross-species microRNA quantification. - Kaadt E; Søkilde RF; Garling HD; Raval NR; Lundgaard L; Just J; Knudsen GM; Elfving B. (European journal of pharmacology, 2026)

Effects of naturalistic psychedelic use on executive functioning: An online survey of lifetime history and recent use in university students. - Todesco S; Allan Z; Liu MYM; Schütz C. (Progress in neuro-psychopharmacology & biological psychiatry, 2026)

Psychedelics and astrocytes: a hypothesis-driven perspective on neuro-glial integration, network plasticity, and neuroimmune reprogramming. - Ke X; Du X; Wang X. (Molecular psychiatry, 2026)

Psilocybin Recovery Intervention for Stopping Methamphetamine Use - Nicky Mehtani; MD; MPH (ClinicalTrials.gov, 2026)

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis - Johns Hopkins University (ClinicalTrials.gov, 2026)

Could Psilocybin Be the Key to Treating Anorexia? -Breaking the Mind's Most Stubborn Loop - Ijaz Durrani (2026)

Circulating MicroRNAs and Their Associations with Neurotrophic, Inflammatory and Glutamate Markers in Healthy Volunteers - O’Shea A; Mason NL; Briede JJ; Schreiber R; Verheijen MC; Krauskopf J; Ramaekers JG. (bioRxiv, 2026)

Temporal effects of a single oral dose of psilocybin on plasma circulating miRNAs in healthy young adults - O’Shea A; Mason N; Schreiber R; Verheijen MC; Ramaekers JG; Briedé JJ; Krauskopf J. (bioRxiv, 2026)

Psilocybin acutely dissociates cognitive and affective empathy, with empathic concern predicting persisting positive psychological effects - Mason N; Mallaroni P; Kuypers K; De La Torre Fornell R; Reckweg J; Preller K; Ramaekers J. (bioRxiv, 2026)

An Open-Label Trial Protocol to Test Menstrual Cycle Effects and Tolerance to Low-Dose Psilocybin in Healthy Menstruating Persons. - Kothiwala FM; Murphy RJ; Alshakhouri M; Douglass HM; Evans WJ; Paterson T; Muthukumaraswamy S; Sumner RL. (Pharmacology, 2026)

An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study) - Charles Raison (ClinicalTrials.gov, 2026)

A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2026)

Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury - James J. Peters Veterans Affairs Medical Center (ClinicalTrials.gov, 2026)

A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2026)

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults - University of Colorado; Denver (ClinicalTrials.gov, 2026)

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study - University Health Network; Toronto (ClinicalTrials.gov, 2026)

'So many relationships in the room': Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy. - Ham R; Gardner J; Carter A; Liknaitzky P. (Psychology and psychotherapy, 2026)

Advanced research eyes potential of psychedelics for complex cases - Gary Enos (Mental Health Weekly, 2026)

Microdosing psychedelics: What, why, when, and how often? Insights from an international survey of people who use psychedelics. - Petranker R; Syed OA; Sobolenko V; Giacobbe P; Kruger DJ; Aday JS; Lake S; Lucas P. (The International journal on drug policy, 2026)

Feasibility and Tolerability of Psilocybin for Phantom Limb Pain. - Dean JG; Hurwitz E; Furnish T; Castellanos J; McKinty A; Farrell B; Barrows D; Peck SK; Trim J; Samadhi E; Renwick G; Mudge R; et al. (The journal of pain, 2026)

Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study. - Bhagavan C; Carter O; Nielsen G; Berlowitz D; Issak S; Braat S; Zaloumis S; Attard Z; Oliver G; Mayne D; Rucker J; Butler M; et al. (CNS drugs, 2026)

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease - National Institute on Aging (NIA) (ClinicalTrials.gov, 2026)

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease - Joshua Woolley; MD; PhD (ClinicalTrials.gov, 2026)

Open Label Psilocybin Brain Stimulation and Imaging Pilot Study - Johns Hopkins University (ClinicalTrials.gov, 2026)

Therapeutic potential of classic and non-classic psychedelics in neurodevelopmental disorders: Opportunities and challenges. - Giovenzana M; Nicosia N; Spinosa S; Musazzi L; Mingardi J. (Pharmacological research, 2026)

Correspondence: "Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy". - Hörnqvist N. (Journal of affective disorders, 2026)

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial. - Rucker JJ; Mantingh T; Kerr-Gaffney J; Bird C; Chu P; Modlin NL; Campbell-Coker K; Hambleton S; Seath P; Hignett R; Fennema D; Hampsey E; et al. (Nature medicine, 2026)

Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder - Trent Emerick (ClinicalTrials.gov, 2026)

Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy - University of Southern California (ClinicalTrials.gov, 2026)

A suite of engineered mice for interrogating psychedelic drug actions. - Chiu YT; Deutch AY; Wang W; Schmitz GP; Huang KL; Kocak DD; Llorach P; Bowyer KR; Liu B; Sciaky N; Hua K; Chen C; et al. (Nature neuroscience, 2026)

Mapping excitatory synaptic plasticity evoked by single-dose psilocybin in mice - Li; Z.; Weber; C.; Sellitti; F.; Simmler; L. D. (bioRxiv, 2026)

Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs. - Ippolito A; Tiranti A; Hurley S; Gilmour G; Churchill G; Sharp T (ACS chemical neuroscience, 2026)

Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer - Yvan Beaussant; MD; MSci (ClinicalTrials.gov, 2026)

Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review. - Thomas JE; Dellarole A; Caballero J (American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists, 2026)

Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies - University of New Mexico (ClinicalTrials.gov, 2026)

Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability. - Kuypers KPC; Mason NL; Carlier A; Totomanova I; Haijen-Bongers ECHM. (Molecular psychiatry, 2026)

Simulated 5-HT2A receptor activation accounts for the high complexity of brain activity during psychedelic states - Martin; H. M.; Cofre; R.; Destexhe; A. (bioRxiv, 2026)

Serotonergic psychedelics induce distinct patterns of metabolic activity and covariance within biologically informed rat brain networks - Frederik Gudmundsen; Julia Czurylo; Daniel Ryskamp Rijsketic; Camilla Trang Vo; Janika Ruuska; Naja S. Jessen; Sophie Woodruff; Christina Baun; Matthias M. Herth; Vladimir Shalgunov; Boris D. Heifets; Patrick M. Fisher; et al. (Nature Communications, 2026)

Music for Psilocybin Therapy and the Temporal Arc of Psychedelic Experience - Gómez-Cañón JS; Leininger C; Mayall D; Dougherty RF; Bowling DL. (Research Square, 2026)

Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis. - Schaefer DA; Agrawal M; Mazzola E; Leff MK; Leeks C; Kematick BS; Beaussant Y. (Journal of pain and symptom management, 2026)

Where is the sweet spot for psychedelic-enhanced fear extinction? An integrative quantitative synthesis of dose-effect patterns in rodent models. - Werle I; Probst MEC; Bertoglio LJ. (Journal of psychopharmacology (Oxford, England), 2026)

Psilocybin as a Treatment for Chronic Pain in Smokers - Yale University (ClinicalTrials.gov, 2026)

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study - Oregon Health; Science University (ClinicalTrials.gov, 2026)

Evaluating psilocybin for the management of depression: a literature review - Sinclair Rachel (British Journal of Mental Health Nursing, 2026)

Psilocybin for Fear of Cancer Recurrence - Cho Matthew; Rosenbaum Daniel; Hapke Emma; Hales Sarah (Supportive Care in Cancer, 2026)

One Dose of Psilocybin May Alter Brain Structure - Karel Richard B. (Psychiatric News, 2026)

Cardiovascular safety of psilocybin in psychiatric practice: a narrative review - Szarpak Lukasz; Pruc Michal; Swieczkowski Damian; Rybczynski Bernard; Pieta Aleksandra; Cubała Wiesław Jerzy (European Journal of Clinical Pharmacology, 2026)

From trial to clinic: psilocybin's efficacy in routine treatment-resistant depression. - Martiadis V (The Lancet regional health. Europe, 2026)

Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study - Chwyl Christina; Bazinet Alissa; Wilson-Poe Adrianne R.; Hoffman Kim; Pertl Kellie; Wolf R. Cameron; Korthuis P. Todd; Luoma Jason B. (Neuroethics, 2026)

Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature. - Kase M; Kaup KK; Aru J (Journal of psychopharmacology (Oxford, England), 2026)

In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5’-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin - Jurowski Kamil; Kobylarz Damian; Noga Maciej (Archives of Toxicology, 2026)

Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanisms - Akbar Razeen J.; Stringer Amy D.; Wiah Sonita; Dachepalli Meghana; Daws Stephanie E.; Inan Saadet; Rawls Scott M. (Behavioural Pharmacology, 2026)

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects. - Hampsey E; Martin K; Kalfas M; Benson L; Wihlborg S; Jelen L; Young AH; Rucker J (Journal of psychopharmacology (Oxford, England), 2026)

Classic psychedelics and personality: An updated systematic review. - Vicentini AB; de Paula CC; Silva Reis JA; Bouso JC; Hallak JEC; Dos Santos RG (Journal of psychopharmacology (Oxford, England), 2026)

Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians. - Boehnke KF; Pouyan N; Aday JS (Drugs, 2026)

Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus. - Lu S; Zhang Z; Xue X; Jiang Y; Zhang C; Liu P; He D; Shen W; Yang S; Wang F (Hearing research, 2026)

Pharmacokinetic and pharmacodynamic rational for expanding the therapeutic landscape of psilocybin beyond depression - Mingardi J.; Molteni R.; Bifari F. (Pharmacological Research, 2026)

Barriers and Facilitators for Psychedelic Research and Regulation in Brazil: Insights From Diverse Stakeholders. - Guimarães AL; Beserra FR; Cruz L; Bienemmann B; Freind JMK; Guinle V; Rodrigues RS; Regalado JA; Mograbi DC (Clinical therapeutics, 2026)

Anxiety-related platform in zebrafish (Danio rerio) larvae: An integrated analysis of behavioural and molecular assay in drug screening research. - Potoczna M; Kasica N; Chmielewska-Krzesińska M; Dybalska-Szczepanek J; Wąsowicz K; Sokołowska E; Podlasz P (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026)

Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis - Kishi Taro; Sakuma Kenji; Hatano Masakazu; Uchida Hiroyuki; Iwata Nakao (Journal of Affective Disorders, 2026)

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis - Goodwin Guy M.; Aaronson Scott T.; Alvarez Oscar; Carhart-Harris Robin; Croal Megan; Feifel David; Hellerstein David J.; Husain Muhammad I.; Kelly John R.; Kirlic Namik; Licht Rasmus W.; Marwood Lindsey; et al. (Journal of Affective Disorders, 2026)

A25-year analysis of Armillaria (honey mushroom) poisoning in Wisconsin. - Feldman R; Audette M; Leacock PR; Theobald J (The American journal of emergency medicine, 2026)

Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025. - Berg CJ; LoParco CR; Rossheim ME; McCready DM; Langan L; Platt E; Romm KF; Johnson M; Speer MB; Burris S; Cavazos-Rehg PA (Drug and alcohol dependence, 2026)

A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study. - Graham M; Ge Y; Pacula RL; Pessar SC; Wilkins C; Hall W; Hammond D (The International journal on drug policy, 2026)

The Experience-Trajectory Framework: Substance-Specific Risk Stratification for Psychedelic Preparation and Aftercare Beyond Set and Setting - Eric P. Rubenstein (International Journal For Multidisciplinary Research, 2026)

A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression - University of Washington (ClinicalTrials.gov, 2026)

Retreat from racism: A psychedelic group experience for racial stress and trauma - Sergio R Pérez Rosal; Sonya Faber; M. Myriah MacIntyre; Monnica Williams (Psychedelics, 2026)

Beyond psilocybin: Do magic mushroom preparations contain other compounds with pharmacological effects? - Lasham S; P B; W E; C P; A S; R P. (Authorea Preprints, 2026)

Shrooming Ahead: How the U.S. is Marching Toward Psilocybin Legalization and What Other Countries May Learn - Titus Scheid (eYLS (Yale Law School), 2026)

Childhood trauma and psychological outcomes following psychedelic use: a scoping review - Lorraine Li; Paige Seath; Nadav Liam Modlin; James Rucker (npj Mental Health Research, 2026)

Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression - Joshua Rosenblat (ClinicalTrials.gov, 2026)

Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder - Tel-Aviv Sourasky Medical Center (ClinicalTrials.gov, 2026)

Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial - Armstrong Stacey B.; Levin Adam W.; Sepeda Nathan D.; Shaub Hillary; Hunter Taweh; Douglas Angela; Lancelotta Rafaelle; Davis Alan K. (Communications Medicine, 2026)

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from Jamaica - Sams Caitlyn Hanna; Davis Jasmine; Ramdas Anuradha; Delgoda Rupika; Vidot Denise; Reid Marvin; De La Haye Winston (Frontiers in Psychiatry, 2026)

An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD - Scottsdale Research Institute (ClinicalTrials.gov, 2026)

Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

Is BOLD Measurement-Invariant Across Pharmacological State? A Pre-Registered Test of Haemodynamic Response Function Drug-Invariance Using Simultaneous EEG-fMRI (PsiConnect) - Kareem Soliman (Open MIND, 2026)

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics. - Jones GH; Gilbert JR; Johnston JN; Akula N; Schulmann A; Arakelian M; Peng S; Yuan P; Winful EA; Yavi M; Quintanilla B; Elkahloun A; et al. (Molecular psychiatry, 2026)

Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin. - Pontifícia Universidade Católica do Rio de Janeiro (ClinicalTrials.gov, 2026)

Identifying factors that contribute to the behavioral effects of psilocybin in preclinical mouse models - Fleury S; Chang LJ; Nautiyal KM. (bioRxiv, 2026)

Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortex - Wawrzczak-Bargieła Agnieszka; Jelonek-Kozioł Małgorzata; Kumorek Weronika; Bilecki Wiktor; Maćkowiak Marzena (Psychopharmacology, 2026)

Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions. - Wilkowska A; Nizgorska-Ohler J; Cubała WJ (Molecular neurobiology, 2026)

Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

A Systematic Review of EEG Predictors and Correlates of Psilocybin’s Treatment in Depression - Danial Beniameen; Armya Beniameen (Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, 2026)

Network Pharmacology-Guided Discovery of Fungal Autophagy Modulators for Tauopathies: Structural and Proteomic Evidence - Torres Mc Cook; A. R.; Mimura; C. B.; Alvarez; L. D.; Liberman; A. C. (bioRxiv, 2026)

[Illicit use of classic psychedelics and suicidality: A systematic literature review]. - Pereira de Oliveira AB; Hein M (L'Encephale, 2026)

Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review - Nicholas Vucak; Raimondo Bruno; Julio Quealy; James G. Casimaty; Susan L. Rossell; D Castle; Nicola Acevedo (Psychedelics, 2026)

Participants' Music Experiences Associated With Psychedelic-Assisted Psychotherapy for Life-Threatening Illness: Interpretivist Research. - O'Callaghan C; Kallianis V; Ross M (Journal of music therapy, 2026)

An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life - Charles Raison (ClinicalTrials.gov, 2026)

Psilocybin and Affective Function in Chronic Lower Back Pain Depression - Johns Hopkins University (ClinicalTrials.gov, 2026)

Comparing synthetic and biological therapy for the treatment of cluster headache: what is needed and when? - Parr BA; Young WB; Silberstein SD (Expert review of neurotherapeutics, 2026)

Estimating Cardiac 5-HT2B Safety Margins for Repeated Low-Dose Psilocybin Using an Exposure-Response Model - Tyler WJ; Sellers E; McDonnell MB. (bioRxiv, 2026)

No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study - Bailey Neil Wayne; Webb Samantha Lee; Fitzgibbon Bernadette Mary; Denning Nigel Christopher; Dowie Traill; Schweickle Monica Margaret; Modak Anish; Chan Grace; Knight Jackie; Waldron Molly; Gainsford Kirsten; Hawkes Hannah; et al. (Journal of Psychopharmacology, 2026)

A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. - Francisco A Moreno (ClinicalTrials.gov, 2026)

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought - Johns Hopkins University (ClinicalTrials.gov, 2026)

Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND) - King's College London (ClinicalTrials.gov, 2026)

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD) - Usona Institute (ClinicalTrials.gov, 2026)

A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety - Ohio State University (ClinicalTrials.gov, 2026)

The "dark magic mushroom" co-produces amatoxins and psilocybin. - Kunik AR; Christopher MW; Lemmond B; Dentinger BTM; Slot J; Garrett TJ; Smith ME (bioRxiv: the preprint server for biology, 2026)

Longitudinal neural and psychological changes following psilocybin under compassion imagery priming - Pallavicini Carla; Llobenes Lorena; Cavanna Federico; de la Fuente Laura Alethia; Muller Stephanie; Costa María; Gumiy Natali; Bruno Nicolás; D'Amelio Tomás; Basran Jaskaran; Plowright Ptarmigan; Zamberlan Federico; et al. (Frontiers in Human Neuroscience, 2026)

Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations - Cervera-Sanchez Miguel Benjamin; San-Juan Daniel; Díaz-Peregrino Roberto; Camacho-Castillo Evelin Zulema; Bringas-Ortiz Sthefany Anahi; Padilla-Cabezutd Christian (British Journal of Clinical Pharmacology, 2026)

Psilocybin asymmetrically modulates outcome-based choice and cortical processing under uncertainty. - Jacobs D; Pacheco AT; Olson R; Langdon AJ; Moghaddam B (bioRxiv: the preprint server for biology, 2026)

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment - Johns Hopkins University (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)] - University of California; San Diego (ClinicalTrials.gov, 2026)

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease - Yale University (ClinicalTrials.gov, 2026)

Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors. - Savalia NK; Shao LX; Knox CA; Gilbert AD; Jiang Q; Kwan AC (bioRxiv: the preprint server for biology, 2026)

Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis - Tsang Vivian WL; Kryskow Pamela; Watler Crosbie; Allard Pearl; Dames Shannon (Frontiers in Public Health, 2026)

A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults - Levy-Cooperman N; Sellers E; Glue P; Szeto I; Brown D; Jarecki-Smith J; Tyler WJ; McDonnell MB. (medRxiv, 2026)

Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia - Gattuso James J.; Kamal Ahmed; Payet Jennyfer M.; Havaux Kato; Hendey Jenna; Bezcioglu Bilgenur; Phelan Zoe J.; Orchard Maddy; Bhanot Divyesh; Hale Matthew W.; Hannan Anthony J.; Renoir Thibault (Neuropsychopharmacology, 2026)

Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of Depression - Bartosz Niciński; Magdalena Kloc; Ewa Wiench; Natasza Millan; Aleksandra Blicharz; Wojciech Kozdraś; Lidia Kozaczko; Gabriela Szewczyk; Elżbieta Bukowczan; Alicja Zając; Damian Broda; Alicja Benecka (Zenodo (CERN European Organization for Nuclear Research), 2026)

A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin - Diamond Therapeutics Inc. (ClinicalTrials.gov, 2026)

Publication bias in randomized trials of psilocybin for depression: a Robust Bayesian Meta-Analysis - Çağrı Özkurt (PsyArXiv, 2026)

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial - Johns Hopkins University (ClinicalTrials.gov, 2026)

Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder - Jakub Bajer; Aleksandra Włodarczyk; Hubert Kulawinek; Julia Obersztyn; Krzysztof Kasparek; Marta Czech; Grzegorz Kasparek; Adrianna Szczecińska; Wiktoria Glanert; Aleksandra Mliczek; Piotr Mrozek (Journal of Education Health and Sport, 2026)

Integrated 5-HT-TrkB and G protein signaling in serotonergic psychedelic responses. - Taddei-Tardón M; Medina-Rodríguez L; Maltman JL; Hudson S; Potukanuma S; Hidalgo Jiménez J; Martín-Guerrero SM; González-Maeso J; López-Giménez JF (Molecular psychiatry, 2026)

Uncovering the spatiotemporal structure of neural avalanches through optimal transport and dynamic time warping - Novicky F; Jajcay N; Hlinka J. (bioRxiv, 2026)

Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder - Dougherty Robert F.; Modlin Nadav Liam; McGowan Niall M.; Staples Patrick; Williams Ella; Clarke Patrick; Shafiei Mario; Leininger Carly; Alti Merve; Croal Megan; Marwood Lindsey; Kirlić Namik; et al. (Journal of Psychopharmacology, 2026)

Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes - Yale University (ClinicalTrials.gov, 2026)

The ANCHOR Framework for Psychedelic Accompaniment - Ron Shore (PsyArXiv, 2026)

Psilocybin's effect on human brain synaptic plasticity. - Johansen A; Plavén-Sigray P; Madsen MK; Søndergaard A; Messel C; Geisler M; Nasser A; McCulloch DE; Beliveau V; Vassilieva A; Lund A; Lehel S; et al. (Translational psychiatry, 2026)

Shurooms: The First Ethnomycological Study from Within the African Initiatory Tradition - Ewe, Soma, and the Ceremonial Architecture of Psilocybin Healing (N = 300+) - Shumake; Robert S. (Ajarn Shaman Shu | Oluwo Jolaoso Osainbola; PhD | Shri Suryanarayana Swamikal) (Zenodo (CERN European Organization for Nuclear Research), 2026)

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial - Khyber Medical University Peshawar (ClinicalTrials.gov, 2026)

Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study. - Zarrabi AJ; Mletzko T; Grant G; Peacock C; Palitsky R; McPherson T; Shub I; Eisenacher S; Maples-Keller JL; Kaplan D; Rothbaum BO; Rab F; et al. (medRxiv: the preprint server for health sciences, 2026)

Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female Participants - Mason NL; Haijen-Bongers EC; Kuypers KP; Frick A; Toennes SW; Mallaroni P; Ramaekers JG. (bioRxiv, 2026)

Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview - Hörnqvist Nils (Journal of Psychedelic Studies, 2026)

Mechanistic Studies of Psilocybin in Headache Disorders - Yale University (ClinicalTrials.gov, 2026)

MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments - Brinzei OV. (ScienceOpen Preprints, 2026)

Psilocybin-induced behavioral and cellular effects - Dong Albert M.; Han Yi; Xu Zheng; Schlüter Oliver M.; Huang Xiaojie (Journal of Neurogenetics, 2026)

National bill seeks to jump-start psychedelic treatment for veterans - Gary Enos (Alcoholism & Drug Abuse Weekly, 2026)

Psilocybin bei Depression: Systematisches Review und Meta-Analyse zur antidepressiven Wirksamkeit - Nele Böhm; Frank Euteneuer (OSF, 2026)

Epigenetic landscapes of classical psychedelics and ketamine: molecular mechanisms of long-lasting neuromodulation. - Lin C; Wang X (Molecular psychiatry, 2026)

Psychedelics produce enduring enhancement of reward responsiveness in male rats. - Thomas CW; LaMalfa KS; Whelan TP; Blackmore T; Golden CT; Pizzagalli DA; Bergman J; Gilmour G; Kangas BD (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2026)

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial - Bruyère Health Research Institute. (ClinicalTrials.gov, 2026)

PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial - Ottawa Hospital Research Institute (ClinicalTrials.gov, 2026)

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain - University of California; Berkeley (ClinicalTrials.gov, 2026)

Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling. - Liu C; Ho EM; Enos AS; Baublyte UB; Luna IM; Kosche AR; Sohal VS (bioRxiv: the preprint server for biology, 2026)

Therapeutic potential of psilocybin in the pharmacological treatment of obsessive-compulsive disorder: a scoping review protocol. - Raul Edison Luna Lazo; Nicole Milagritos Cardoso Azorza; Jatziri Yanina Vilca Yanac; Ahmad Kassem El Zein; Omar Abraham Ramírez Paucar; Luana Mota Ferreira; Roberto Pontarolo (Open MIND, 2026)

The Effects of Psilocybin on Social Connectedness - Yale University (ClinicalTrials.gov, 2026)

First molecular record of Panaeolus subbalteatus (Psathyrellaceae, Agaricales) from Pakistan. - Rukhsar S; Yousaf N; Sadaf; Fazal M; Hanif M; Muhammad M; Egamberdieva D; Li WJ (Antonie van Leeuwenhoek, 2026)

Psychedelics stores, their regulation and public health: knowledge, perceptions, attitudes and opinions of Canadians. - Gagnon F; Philibert A; Carignan B; Labonté E; Dufresne Y (The International journal on drug policy, 2026)

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2) - University Health Network; Toronto (ClinicalTrials.gov, 2026)

Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects - Yale University (ClinicalTrials.gov, 2026)

Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder - University of Pennsylvania (ClinicalTrials.gov, 2026)

Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin. - Baker JJ; Kogan E; Ma S; Lu J; Zuo Y (bioRxiv: the preprint server for biology, 2026)

Entourage-Psilocybin-Ganzpilz - Schüller Thomas (Zenodo (CERN European Organization for Nuclear Research), 2026)

Psilocybin therapy for adult females with anorexia nervosa: pilot study - Douglass Hannah M.; Spriggs Meg J.; Godfrey Kate; Danby Jennifer L.; de Magalhaes Frederico J. C.; Macdonald Lauren; Alderton Kirsty L.; Archer Stephanie; Ahmad Kirran; Martell Jonny; Frias Jennifer T.; Sawicka Gabriela; et al. (The British Journal of Psychiatry, 2026)

Synthesis and Biological Evaluation of 4-Bromo-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development. - Bray E; Glatfelter GC; Maitland AD; Gonzalez NR; Walther D; Yacoub J; Baumann MH; von Salm JL (ACS omega, 2026)

α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice - Rosado Axel F.; Yu Abigail L.; Yang Jen-Hau; Rondeau Jocelyne; Floris Gabriele; Basu Aakash; Staszko Stephanie; Dibbs Mark; Feng Jiesi; Li Yulong; Warner-Schmidt Jennifer; Kelmendi Benjamin; et al. (Molecular Psychiatry, 2026)

CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder - Paslawski Wojciech; Doyon Daniel; Ekman Carl Johan; Yngwe Hampus; Mamula Dejan; Zareba-Paslawska Justyna; Beckman Maria; Xu Zhi-Qing David; Hökfelt Tomas; Tiger Mikael; Lundberg Johan; Svenningsson Per (Neuropsychopharmacology, 2026)

Caution in interpreting value-related change after psilocybin: Comment on Kerr-Gaffney et al. (2026) - Tahamtan Golnush; Chernoloz Olga (Journal of Psychopharmacology, 2026)

Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation - University of Wisconsin; Madison (ClinicalTrials.gov, 2026)

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) - Yale University (ClinicalTrials.gov, 2026)

The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer - Adler Hannah; Filipic Rebecca; Gonzalez Maria; Kwon Ki; Lacey Judith; McDonald Geraldine; Sarris Jerome; Chmiel Katarzyna; Low Mitchell; Sinclair Justin; Grant Suzanne (BMC Medicine, 2026)

Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review - Omar Azuara-Antonio; Erika Rubí De La Cruz-Elizaldeb; José Eduardo Carmona-Rodriguez; Lesly Idaliht Hernandez-Martinez (Mexican Journal of Medical Research ICSA, 2026)

Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development - Enriquez-Geppert Stefanie; Bevers Lisa; Rosander Arvid; Fodran Peter; Polito Vince (Biomolecules, 2026)

Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions - Whitfield Henry J.; Schepers Jan; Mason Natasha L.; Luca Maria; Kuypers Kim P. C. (Journal of Psychedelic Studies, 2026)